《美股業績》安進(AMGN.US)季績勝預期 上調全年業績預測
道指成分股安進藥廠(Amgen)(AMGN.US)公佈第二季業績,淨利潤按年升近5%至13.79億美元,每股季度攤薄純利2.57美元,經調整後爲5美元,高於市場預期的4.46美元。季度收入按年升6%至69.86億美元,高於市場預期的66.8億美元。
季度產品銷量按年升11%,但淨銷售價格按年跌2%,匯率及低庫存亦影響銷售增長。公司於下降膽固醇藥Repatha季度銷售4.24億美元,骨質疏鬆症注劑Prolia季度銷售10.3億美元,兩者銷售均高於市場預期。但關節炎藥Amjevita季度銷售1.5億美元,遜於市場預期的逾2億美元,主要受庫存不足拖累。
公司預測全年經調整每股盈利介乎17.8至18.8美元,高於原來預測介乎17.4至18.6美元;全年收入料介乎266億至274億美元,高於原來預測介乎260億至272億美元。
公司目前預期12月中完成對Horizon Therapeutics的收購。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.